The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
about
The role of drug transporters in the kidney: lessons from tenofovirTenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic StudyLong-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical PracticeEffect of changing from first- to second-line antiretroviral therapy on renal function: a retrospective study based on data from a single health facility in Namibia.Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitorsRenal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapineDeterminants of individual variation in intracellular accumulation of anti-HIV nucleoside analog metabolites.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trialCystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial.A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patientsAssessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.Nephrotoxicity of HAARTCommentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy.Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patientsPhysiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function ImpairmentPharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.Individualization of antiretroviral therapy.Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in BotswanaAge-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adultsReview of tenofovir-emtricitabine.Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyTenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infectionInfluence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
P2860
Q26866489-5DCB3DA5-2DB9-4DDF-B581-85E1145E6F72Q26995852-F25EF78D-CD6F-42EF-9C59-F5F3E2D42E0AQ28533843-52E15412-4E84-4DF2-A509-F513871D6893Q28550681-351A88CB-4743-402A-A515-59232CE24B27Q28554567-5686B938-E2C8-4559-BFE6-F7EA94621DBEQ31108490-45A1F0C4-EDF7-4B6B-9D0A-EA0457AC5BD2Q34136166-5E9B819F-2C11-451C-A4F7-D7696E0F8F1CQ34250879-D544DC4F-F784-4CFE-AACA-840CC072FF83Q34529268-D2D59149-EE09-47B1-B26F-5AC74C54468EQ34736194-BE0AD5A7-D8AC-4B31-B107-06CEB34654DBQ34787977-A6790CE7-8D4B-45F5-8447-5C56CD3BC63EQ34952127-8DD3D000-42A8-4B18-A662-2DCC11EDB04CQ35071954-7D8A7A85-58A6-4C99-9F52-3818874AC68FQ35091774-68F87E4C-5B4E-445D-B01D-087AF4F64F2CQ35102254-B4B4675C-C310-4BE4-99A7-9A789263902BQ35126728-26BA4A27-6AC7-460B-967D-679103BAD739Q35155913-93E3BD60-128B-471F-B7B5-A0EA2222A6E7Q35167944-1D317FF9-A255-4F24-973E-0BF8AC5CB33CQ35171168-7A259C71-1F48-4E05-8141-3AEC88B177FEQ35363649-1DED9F34-0782-4DF6-9F9F-B42C54A6C9B8Q35607723-1AD5A840-F192-483E-AA46-7AA1E3FFAECFQ35668556-539C6014-D03B-480C-96F3-F509C782DFE7Q35770848-67FCE705-C279-481A-9F15-20A07A32047BQ35823231-92757910-73E3-4973-B0FF-A955FE30478AQ35908584-9EA0BC06-7B82-46B7-B096-BB6201F019C4Q36167503-ECDF7CF5-3FBF-4477-95D7-EAAAB40225B1Q36425083-FFF5791C-08F5-4952-B11C-27FF7A15330EQ36441423-0A2BE1F7-CF47-4EC5-ABA8-99609CF24191Q36619600-F4F3F741-C7E4-4429-A6DB-D584E903CB6CQ36650454-59ABD94B-6CA0-4708-9C6F-327A8C6AA080Q36663686-913D237E-337F-4AAA-9A29-0B6D3928A6F1Q36721002-1C6ECE9C-01D7-4140-BAB0-E097190780DFQ36721012-D5D71B09-E7B7-4314-8B0D-4ECC2474FF1AQ36757558-9D775910-B068-441E-B986-06D7745C737DQ36876279-7F4F26B4-90A1-430A-BFAB-8B6C56C7BC61Q36988748-D8A7453E-08AF-4C50-A21A-6CF08B840649Q37014157-54075DFF-F260-4C11-AA10-1E66388D6653Q37113947-A5C0F21D-5E88-4BD3-A3FC-A35616B4389DQ37190767-991F0B3B-D6B6-415B-9B1C-CB1CD894B941Q37204271-8AE1A09E-7ED1-4941-84EA-BE1F3E1938AB
P2860
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The effect of lopinavir/ritona ...... ovir in HIV-infected patients.
@en
type
label
The effect of lopinavir/ritona ...... ovir in HIV-infected patients.
@en
prefLabel
The effect of lopinavir/ritona ...... ovir in HIV-infected patients.
@en
P2093
P356
P1476
The effect of lopinavir/ritona ...... ovir in HIV-infected patients.
@en
P2093
C L Aquilante
C V Fletcher
L R Bushman
M L Carten
P L Anderson
T Delahunty
P2860
P304
P356
10.1038/SJ.CLPT.6100269
P407
P577
2007-06-27T00:00:00Z